Tizanidine Co-Prescribing With Losartan and Metoprolol
Tizanidine can be co-prescribed with losartan and metoprolol in an adult without liver disease when strong CYP1A2 inhibitors are not used and when baseline hypotension or bradycardia is not present. [1] Tizanidine may still cause hypotension and bradycardia, so blood pressure and heart rate monitoring and dose reduction or discontinuation are indicated if these adverse effects occur. [1]
Interaction With CYP1A2 Inhibition
Concomitant use of tizanidine with strong CYP1A2 inhibitors is contraindicated because CYP1A2 inhibition increases tizanidine exposure and is associated with clinically significant decreases in blood pressure and increased sedation. [1] In a retrospective cohort study of patients receiving a strong CYP1A2 inhibitor, severe hypotension (systolic blood pressure ≤70 mmHg during co-exposure) occurred more often with tizanidine than with cyclobenzaprine (2.03% vs 1.28%; odds ratio 1.60; P=0.029). [2]
Medication Selection Algorithm
- Tizanidine should not be co-prescribed with strong CYP1A2 inhibitors (examples include fluvoxamine and ciprofloxacin). [1]
- Tizanidine should be used with caution with agents that increase risk of hypotension or bradycardia because tizanidine can produce hypotension and bradycardia. [1]
- Losartan and metoprolol do not have a stated CYP1A2-specific interaction with tizanidine in the labeling sources reviewed, so major interaction avoidance depends primarily on CYP1A2 inhibitor status and baseline hemodynamics. [1]
Monotherapy Versus Combination Therapy
Combination therapy is permissible when the main contraindication condition is absent (no strong CYP1A2 inhibitors) and when baseline hypotension and bradycardia are not present. [1] Even when baseline hemodynamics are stable, tizanidine should be managed as a blood pressure–lowering agent that can also cause bradycardia, making combination use with antihypertensive and rate-slowing therapies dependent on monitoring and adverse-effect management. [1]
Important Clarifications and Nuances
Tizanidine is an α2-adrenergic agonist and can produce hypotension. [3] In pharmacology data summarized in product labeling, a single dose of 8 mg tizanidine was associated with a ≥20% reduction in systolic or diastolic blood pressure in two-thirds of patients in a monitored single-dose study, with effects beginning within 1 hour and peaking at 2 to 3 hours. [3] Tizanidine-associated hypotension can be orthostatic and can occur with or without bradycardia. [3]
Treatment Initiation Thresholds
There is no dose-independent “safe threshold” in the reviewed sources. [1] Initiation or continuation should be avoided or dose-reduced if hypotension or bradycardia develops after tizanidine use, because these adverse reactions are specifically referenced as indications to reduce or discontinue therapy. [1]
Common Pitfalls to Avoid
Co-prescribing tizanidine with strong CYP1A2 inhibitors is a primary pitfall because the combination is contraindicated and is associated with severe hypotension during co-exposure. [1] Continuing tizanidine despite hypotension or bradycardia is another pitfall because the labeling recommends dose reduction or discontinuation if such adverse reactions occur. [1]
Target Goals of Therapy
The immediate therapeutic goal is prevention of tizanidine-associated adverse effects, specifically clinically significant hypotension and bradycardia. [1] If hypotension or bradycardia occurs, management should target resolution of these events through dose reduction or discontinuation of tizanidine. [1]